Ouro Fino Saúde Animal Participações S.A.

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2021

In its 2023 reporting, Ouro Fino Saúde Animal Participações S.A. disclosed greenhouse gas emissions of 5.2K tCO2e/year. By scope: Scope 1: 5.2K tCO2e/year; Scope 2: 27.79 tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
5.2K tCO2e/year
2023
⚡
Renewable Energy
100% (Cravinhos)
of total energy
💧
Water Usage
122.9K m3/year (Cravinhos)
2023
♻️
Waste
463.7K tons/year (non-hazardous Cravinhos); 311848 tons/year (hazardous)
2023
⚙️
Energy Use
1.7K MWh/year (Cravinhos)
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).5.2K tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.27.79 tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
20235.2K tCO2e/year
20217.604,12 tCO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🌱 ESG Focus Areas

Animal WelfareWell-being and Appreciation of PeopleFood Safety and SecurityClimate ChangeResearch and DevelopmentSupply Chain Management

⚠️ Challenges & Risks +

  • Adverse market conditions impacting business performance (high interest rates, export interruptions, drought).
  • Reduced demand in the companion animal segment.
  • Supply chain disruptions.
  • Potential water scarcity.
  • Climate change impacts on agriculture and animal health.
  • Regulatory changes (e.g., suspension of mandatory foot-and-mouth disease vaccination).
  • Dependency on active ingredient suppliers in China and India.
  • Complexity of biologics production.
  • Reputation risks (accidents, ethical violations, third-party misconduct).
  • Reduced profitability margin due to competition and increased costs.

📋 Report Information

Reporting Period: 2023
Frameworks: GRI Standards, IIRC Integrated Reporting, UN Sustainable Development Goals (SDGs)
Assurance: BLB Auditores e Consultores (limited assurance for non-financial information)